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Abstract Cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL)
is an inherited microangiopathy caused by NOTCH3
mutations. It is characterized by migraine, with or without
aura, ischemic events, psychiatric and cognitive distur-
bances. There is no approved treatment for migraine pro-
phylaxis in CADASIL, but acetazolamide has been
anecdotally reported to be effective. We retrospectively
reviewed our database of patients with a genetic diagnosis
of CADASIL to identify how many of them were treated
with acetazolamide for the prophylaxis of migraine. The
efficacy and the tolerability of this treatment were checked
looking at the clinic reports. Acetazolamide was prescribed
in seven patients; the mean duration of treatment was
6 months, and the daily dose ranged from 125 to 500 mg.
Three patients had a total and sustained remission, while in
two patients a reduction in attacks and an improvement of
the headache intensity were recorded. In one of these,
acetazolamide was deliberately taken only during the
migraine attack and the beneficial effect started 1 h after
administration. In two patients, the drug did not produce
any beneficial effect. Mild side effects were recorded in
two patients. Our preliminary experience expands previous
reports and confirms the possible efficacy of acetazolamide
in CADASIL migraine. Based on these data, a randomized
controlled trial seems worthy to be carried out to test the
efficacy and safety of this drug.
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Introduction
Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL) [MIM
125310] is an autosomal dominant microangiopathy caused
by mutations of the NOTCH3 gene that is located on
chromosome 19 and encodes a transmembrane receptor.
The clinical spectrum of the disease includes migraine with
and without aura, early onset cerebrovascular events, mood
disturbances, apathy, cognitive impairment and, more
rarely, epilepsy [1, 2]. The typical neuroimaging findings
on magnetic resonance imaging (MRI) consist of multifo-
cal and bilateral FLAIR/T2-weighted hyperintensities in
the white matter, often involving the anterior temporal
poles and the external capsules. Focal hypointensities on
T1 (evidence of lacunar infarcts) and lesions suggestive of
microhemorrhages in gradient echo images are also seen
[3, 4].
A large number of CADASIL patients suffer from
migraine. Migraine is frequently the presenting disturbance
of the disease, developing in many patients in the second or
third decades of life. In CADASIL, migraine with aura is
particularly common and a large proportion of patients
experience atypical patterns of aura such as aura without
headache, basilar and hemiplegic migraine, and attacks of
prolonged aura [5]. Recently, cases of persistent aura,
status migrainous [6] and acute confusional migraine [7]
have also been described in CADASIL patients. Despite
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migraine is not the most disabling disturbance of CADA-
SIL, it may cause persistent discomfort to patients, espe-
cially in those with frequent attacks, and may lead to
hospitalization, especially because some auras are difficult
to differentiate from cerebrovascular events in these
patients. In CADASIL, the coexistent of migraine, cere-
brovascular events, and microangiopathy is also a point of
interest as far as pathogenesis is concerned.
There have been anecdotic reports on the efficacy of
acetazolamide as a treatment of migraine in CADASIL [8,
9], but no further study has explored this aspect. We have
thus retrospectively reviewed our database of CADASIL
patients to assess how many of them had been treated with
acetazolamide for migraine and the efficacy and tolerability
of this therapy.
Methods
For the purpose of our survey, we retrospectively reviewed
our database of patients with a genetic diagnosis of CA-
DASIL. The efficacy and the tolerability of acetazolamide
treatment were checked looking at the clinic reports. To
assess the success of acetazolamide treatment, we evalu-
ated the number and the quality of migraine attacks after
starting this prophylactic treatment. We classified as with
‘‘significant improvement’’ all patients in whom no further
attack was recorded at subsequent visits and with
‘‘improvement’’ those in whom there was a reduction in
intensity and/or frequency of attack, but some disturbances
was still recorded. If the file data were incomplete we
directly contacted the patients by telephone.
Results
Our data base includes 51 CADASIL patients. Of these, 32
(63%) had migraine that was classified with aura in 11 of
them. Seven patients resulted to have been treated at some
points with acetazolamide for migraine prophylaxis
(Table 1). Before the introduction of acetazolamide, the
mean frequency of migraine attacks was twice a week
(ranging from 1 attack/month to a daily disturbance). The
duration of migraine attacks differed from one patient to
another, and ranged from 30 min up to 1 week. In five of
seven patients, migraine started in young age. In all
patients, the disturbance worsened over the last years,
intensifying its quality and quantity. Two patients started
experiencing somatosensory auras after having suffered for
many years from migraine without aura. All patients had
used some migraine symptomatic treatment, such as para-
cetamol, non-steroidal anti-inflammatory drugs, or triptans
recording different degrees of response. One patient had T
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been on migraine prophylaxis treatment before starting acet-
azolamide with paroxetine reporting only minimal benefit.
The duration of prophylactic treatment with acetazola-
mide ranged from 3 to 12 months. Drug treatment was
empirically started at low dose (125 mg/day) and gradually
increased according to response or side effects. The daily
dose ranged from 125 to 500 mg, usually given bid.
However, one patient deliberately took the drug only on the
occasion of migraine episodes. In five out of seven patients,
the treatment was effective with an obvious reduction in
the frequency of migraine attacks. In three patients, the
benefit could be appreciated within some days of starting of
the treatment and produced a total and prolonged remis-
sion. In two patients, a reduction in the frequency and
severity of attacks was recorded. In the patient taking
acetazolamide only during migraine attack, the beneficial
effect appeared in about 1 h; her attacks were usually more
prolonged. In two patients, the duration and frequency of
attacks remained unaltered. When considering side effects,
subjective gastrointestinal disturbances were reported by
the patient, who took the drug only on the occasion of
migraine attacks. This patient also had a diagnosis of celiac
disease and severe anxious disturbances. The reported side
effects indeed persisted after a first interruption of aceta-
zolamide, and the drug was then started again because of
worsening of migraine. In another patient, a mild increase
in creatinine levels was recorded and this brought to
decrease the daily dose of the drug from 500 to 250 mg.
Discussion
We have reported our experience with acetazolamide in the
treatment of CADASIL migraine. Our preliminary data cor-
roborate two previous single-case reports on the possible
efficacy of the drug in this condition [8, 9]. Even if our data
derive only from a retrospective database analysis and there-
fore no definitive conclusion can be derived, it has to be noted
that the efficacy of the drug was quite striking with a net
benefit reported by five out of seven patients early after drug
starting. Surprisingly, the rate of side effects reported by our
CADASIL patients appears somehow lower that that expected
at least in common migraine [10].
Acetazolamide is a drug used for a variety of conditions
such as congestive heart failure, some forms of epilepsy,
glaucoma, idiopathic intracranial hypertension, but also
rare diseases, such as acute mountain sickness [11].
When considering central nervous system effects, acet-
azolamide penetrates the blood–brain barrier slowly, cau-
ses carbonic acidosis through carbonic anhydrase inhibition
[12], and induces in normal subjects a considerable
increase in cerebral blood flow by vasodilation. Because of
this effect, acetazolamide infusion is also used to evaluate
the degree of alterations in cerebrovascular reactivity [13,
14]. This effect may depend on a metabolic change induced
by the enzyme blockage through a decrease in perivascular
pH and increasing the concentration of nitric oxide or also
by a direct effect on the wall of small brain arterioles and
arteries [15], the real underlying mechanism still being
unclear [16, 17].
The acetazolamide-dependent cerebral vasoreactivity
has been also assessed in CADASIL. In this disease, the
drug is able to produce an increase in cerebral perfusion as
seen by transcranial Doppler sonography [18], perfusion
MRI [19] or Tc-99m ECD brain perfusion SPECT [20].
One study has investigated acetazolamide efficacy in
sporadic migraine with and without aura, demonstrating a
reduction in the frequency of attacks in both migraine types
[21]. This effect is explained by two possible mechanisms.
The first one sees migraine deriving from cerebral oligemia
[22, 23], and acetazolamide acting through vasodilatation.
The second attributes migraine to a possible disorder of
neuronal ion channels [21]. This last mechanism is the one
thought to be responsible for the acetazolamide mechanism
of action in familial ion channels disorders, such as familial
hemiplegic migraine, hypokalemic periodic paralysis and
episodic ataxia type 2 [24–26]. One can hypothesize that
one of the above-mentioned mechanisms or even both are
present also in CADASIL migraine.
The presence of migraine in CADASIL leads to some
considerations [27]. Today, CADASIL migraine is classified
according to the International Classification of Headache
Disorders (ICHD-2) as Headache attributed to cranial or
cervical vascular disorder. This implies that this disturbance
has a vascular basis. However, it is known that, in this disease,
migraine symptoms precede the onset of ischemic events by
several years, and that the typical CADASIL strokes are
mostly of the subcortical type and associated with lacunar
syndromes, whereas migraine-associated disturbances, such
as dysphasia and visual aura are linked with cortical phe-
nomena [5]. One possible explanation for this seemingly
discrepancy in CADASIL could be to hypothesize the pres-
ence of an ultrastructural smooth muscle cells modification in
the meningeal and cortical vessels [7]. A second hypothesis
sees the presence of a possible neuronal cell dysfunction, such
as the above-reported changes in calcium channels or in glial
sodium channels (seen also in other hereditary diseases like
familial hemiplegic migraine and mitochondrial disorders)
that have been already reported to be related to a higher level
of brain hyperexcitability [28], suggesting a potential role in
CADASIL migraine. The complexity of the migraine mech-
anism in CADASIL is also supported by the recently reported
efficacy of intravenous sodium valproate in one patient with a
combination of seizures and migraine [29].
In conclusion, our data seem to hint at a signifi-
cant effect of acetazolamide in CADASIL migraine
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prophylaxis. Our small series of CADASIL patients
expands the previous literature on the topic, but clearly it is
numerically very limited and retrospective in nature, and
therefore no final conclusion about the use of acetazola-
mide in CADASIL migraine can be drawn at present. An
appropriately sized randomized, double-blind, trial is
therefore needed. When considering the absence of data
and the severity of the disturbance in CADASIL patients,
such a trial appears worthy to be started. In our opinion,
two other reasons make a trial of this type potentially
appealing. First, the systematic and controlled use of
acetazolamide in CADASIL could indirectly provide some
information about the pathogenesis of the disease, partic-
ularly on the role of microvessels. Second, a trial with
acetazolamide could also provide some information about
the possible effect of the drug on other disease distur-
bances. Of note, one preliminary study has already shown
that a 24-week administration of acetazolamide is able to
improve cerebral hemodynamics in CADASIL [18].
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